Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers
ConclusionThe CYP3A4 inhibitor itraconazole has a significant influence on the PK behavior of fuzuloparib, suggesting to avoid using strong CYP3A4 inhibitors simultaneously with fuzuloparib. If it is necessary to use a strong CYP3A4 inhibitor, fuzuloparib would be discontinued and be restored to the original dose and frequency of administration after 5 –7 half lives of CYP3A4 inhibitor stopped.Trial registrationhttp://www.chinadrugtrials.org.cn/index.html, CTR20191271.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | China Health | Drugs & Pharmacology | Fallopian Tube Cancer | Oral Cancer | Ovarian Cancer | Ovaries | Peritoneal Cancer | Study